젬백스

082270KOSDAQ

47.0 / 100

Reference Date: 2026-09-08

Financial Score14.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

jemBucks operates two main business segments: an environmental pollution control division producing chemical filters and air purification systems for semiconductor and display manufacturing, and a biotech division conducting clinical trials for GV1001, a telomerase-derived peptide drug candidate for Alzheimer's disease. The environmental division accounts for 99.2% of 2024 sales with its flagship product, the Chemical Air Filter, while the biotech division focuses on developing next-generation peptide drugs based on GV1001's anti-inflammatory and neuroprotective properties.

Number of Employees

217people

Average Salary

46.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-26.29Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

63.27Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼138.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -58.7% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 10,380Won52-week high 59,30052-week low 9,190

1-month return1.0Point

1m -13.28% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

13 totalPositive 5Neutral 8Negative 0

Positive[기재정정]주요사항보고서(유상증자결정)2026-09-04
Neutral주식등의대량보유상황보고서(일반)2026-09-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28
Positive[기재정정]주요사항보고서(유상증자결정)2026-08-20